{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:44:57Z","timestamp":1759340697061,"version":"3.41.2"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["Study number I12099"],"award-info":[{"award-number":["Study number I12099"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,11,15]]},"abstract":"<jats:p>Fluoroquinolone use in children is limited due to its potential toxicity and negative effects on skeletal development, but the actual effects\/risks of fluoroquinolones on bone growth and the mechanisms behind fluoroquinolone-driven arthropathy remain unknown. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic with a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones.<\/jats:p>","DOI":"10.1128\/aac.00483-22","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:23:31Z","timestamp":1666099411000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2842-9063","authenticated-orcid":true,"given":"Cindy","family":"Fishman","sequence":"first","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica M.","family":"Caverly Rae","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine M.","family":"Posobiec","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan B.","family":"Laffan","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Lerman","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[{"name":"Clinical Sciences, GSK Research and Development, Brentford, Middlesex, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Dumont","sequence":"additional","affiliation":[{"name":"Clinical Sciences, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deatra","family":"Nunn-Floyd","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh J.","family":"Stanislaus","sequence":"additional","affiliation":[{"name":"Nonclinical Safety, GSK Research and Development, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Pharmacovigilance risk assessment: quinolone and fluoroquinolone medicinal products for systemic and inhalation use.","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency. 2018. Pharmacovigilance risk assessment: quinolone and fluoroquinolone medicinal products for systemic and inhalation use. European Medicines Agency, Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-fluoroquinolone-article-31-referral-assessment-report_en.pdf. Accessed 21 May 2021."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0150-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(77)90016-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/030098589002700303"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008x(90)90144-j"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0940-2993(96)80003-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/faat.1995.1146"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.715"},{"key":"e_1_3_3_10_2","volume-title":"FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects.","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. 2018. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. US Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics. Accessed 28 February 2022."},{"key":"e_1_3_3_11_2","volume-title":"Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects.","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency. 2018. Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects. European Medicines Agency, Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/en\/news\/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review. Accessed 1 March 2022."},{"key":"e_1_3_3_12_2","volume-title":"FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients.","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. 2018. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. US Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics. Accessed 28 February 2022."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1995.tb13694.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.208843"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1017\/s1481803500015517"},{"key":"e_1_3_3_16_2","unstructured":"Goldman J Kearns G. 2011. 18th Expert Committee on the Selection and Use of Essential Medicines. Fluoroquinolone use in paediatrics: focus on safety and place in therapy. https:\/\/docslib.org\/doc\/3407957\/fluoroquinolone-use-in-paediatrics-focus-on-safety-and-place-in-therapy."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2013"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Zimmerman EI Dumont E Perry C Tiffany C Scangarella-Oman N Raychaudhuri A Hossain M. 2019. Plasma and urine pharmacokinetic analysis of gepotidacin (GSK2140944) following BID oral dosing in a phase IIa study for treatment of uncomplicated urinary tract infections poster 1480. Abstr IDWeek 2019 Washington DC.","DOI":"10.1093\/ofid\/ofz360.1344"},{"key":"e_1_3_3_22_2","unstructured":"Mushtaq S Vickers A Sadouki Z Cole M Fifer H Donascimento V Day M De Pinna E Jenkins C Godbole G Woodfor N. 2019. In-vitro activities of gepotidacin a novel triazaacenaphthylene and topoisomerase IV DNA gyrase inhibitor against Gram-negative bacteria and Staphylococcus saprophyticus poster P1849. Abstr 29th Eur Congr Clin Microbiol Infect Dis Amsterdam The Netherlands."},{"key":"e_1_3_3_23_2","unstructured":"GSK. 2019. A study to evaluate efficacy and safety of gepotidacin in the treatment of uncomplicated urinary tract infection (UTI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04020341."},{"key":"e_1_3_3_24_2","unstructured":"GSK. 2020. Comparative study to evaluate efficacy and safety of gepotidacin to nitrofurantoin in treatment of uncomplicated urinary tract infection (UTI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04187144."},{"key":"e_1_3_3_25_2","unstructured":"GSK. 2019. A study to evaluate efficacy and safety of gepotidacin compared with ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhea. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04010539."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules180911153"},{"key":"e_1_3_3_27_2","first-page":"624","article-title":"The laboratory rat: relating its age with human\u2019s","volume":"4","author":"Sengupta P","year":"2013","unstructured":"Sengupta P. 2013. The laboratory rat: relating its age with human\u2019s. Int J Prev Med 4:624\u2013630.","journal-title":"Int J Prev Med"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-21"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","unstructured":"Fishman C Caverly Rae JM Posobiec LM Laffan SB Lerman SA Pearson N Janmohamed S Dumont E Nunn-Floyd D Stanislaus DJ. 2022. Novel bacterial topoisomerase inhibitor gepotidacin demonstrates absence of fluoroquinolone-like arthropathy in juvenile rats. Abstr Eur Soc Clin Microbiol Infect Dis-Am Soc Microbiol Joint Conf Drug Dev Dublin Ireland. https:\/\/www.escmid.org\/dates_events\/escmid_conferences\/escmidasm_conference_2022\/paper_posters.","DOI":"10.1128\/aac.00483-22"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1112933"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.S3.973"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.10012"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/516119"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1293\/tox.21.123"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01175-06"},{"key":"e_1_3_3_36_2","first-page":"441","article-title":"Quinolone arthropathy induced by ofloxacin in juvenile rats: a light microscopic study","volume":"30","author":"Cavusoglu I","year":"2000","unstructured":"Cavusoglu I, Kahveci Z, Noyan S, Minbay Z. 2000. Quinolone arthropathy induced by ofloxacin in juvenile rats: a light microscopic study. Turk J Med Sci 30:441\u2013447.","journal-title":"Turk J Med Sci"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1755-1759.2002"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900328"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000205799.35780.f3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1761"},{"key":"e_1_3_3_41_2","first-page":"141","article-title":"Models for the study of tendinopathy","volume":"11","author":"Dirks RC","year":"2011","unstructured":"Dirks RC, Warden SJ. 2011. Models for the study of tendinopathy. J Musculoskelet Neuronal Interact 11:141\u2013149.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317711614"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262339502300315"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2389"},{"key":"e_1_3_3_45_2","volume-title":"ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals\u2014step 5.","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. 2020. ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals\u2014step 5. European Medicines Agency, Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/en\/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-pharmaceuticals-step-5. Accessed 3 August 2022."},{"key":"e_1_3_3_46_2","volume-title":"Use of animals.","author":"GSK","year":"2022","unstructured":"GSK. 2022. Use of animals. GSK, Brentford, Middlesex, United Kingdom. https:\/\/www.gsk.com\/en-gb\/responsibility\/ethical-standards\/use-of-animals\/."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1856"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00483-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00483-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T13:01:42Z","timestamp":1668517302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00483-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,15]]}},"alternative-id":["10.1128\/aac.00483-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00483-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"2022-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00483-22"}}